SGLT2i reduces risk of developing HCC in patients with co-existing T2D and CHB infection - A territory-wide cohort study in Hong Kong.
Sign Up to like & getrecommendations! Published in 2023 at "Hepatology"
DOI: 10.1097/hep.0000000000000404
Abstract: BACKGROUND AND AIMS Type 2 diabetes (T2D) and chronic hepatitis B infection (CHB) are risk factors of hepatocellular carcinoma (HCC). Sodium glucose co-transporter 2 inhibitors (SGLT2i) inhibit HCC oncogenesis in preclinical studies. However, clinical studies… read more here.
Keywords: hcc; t2d chb; existing t2d; sglt2i use ... See more keywords